NEWS
Doramectin
  • Approved Drug Name
    Doramectin
  • CAS NO.
    117704-25-3
  • Quality Standard
    USP, EP, JP
  • Packaging
    100G/Bag, 1000G/Bag
  • Storage Condition
    Shading,Sealing,Store at room temperature
  • Certification
    Ongoing registration

Doramectin(casno.117704-25-3) (Dectomax) is a veterinary drug approved by the Food and Drug Administration (FDA) for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle.
Doramectin(casno.117704-25-3) is used for the treatment and control of internal parasitosis (gastrointestinal and pulmonary nematodes), ticks and mange (and other ectoparasites). Doramectin(casno.117704-25-3) is a derivative of ivermectin. Its spectrum includes: Haemonchus spp., Ostertagia spp., Trichostrongylus spp., Cooperia spp., Oesophagostomum spp., Dictyocaulus viviparus, Dermatobia hominis, Boophilus microplus, Psoroptes bovis, among many other internal and external parasites. It is available in 2 dosage forms: as an injection and as a 5 mg/ml topical solution.
Doramectin(casno.117704-25-3) is an avermectin antiparasitic agent that is often used to treat and control various endoparasites and ectoparasites in cattle. It is also used to treat and control gastrointestinal roundworms, lungworms, mange mites, and sucking lice in swine. The injectable form has shown useful in treating various nematode and arthropod parasites in dogs and cats.
Doramectin(casno.117704-25-3) is also marketed in many Latin-American and some Asia and Africa countries as Doramec L.A. (manufactured by Agrovet Market Animal Health) in an 1% Doramectin(casno.117704-25-3) Long Acting Injectable Solution for cattle, sheep, swine and others. Its oleous carrier confers to Doramec L.A. a slow and prolonged liberation, extending its action up to 42 days.
Doramectin(casno.117704-25-3) is also available for horses as an oral flavored bioadhesive gel under the name Doraquest L.A. Oral Gel. It can be used to control and treat internal parasites as roundworms, lungworms and some external parasites.
Doramectin(casno.117704-25-3) is a macrocyclic lactone with a broad spectrum of activity similar to ivermectin. It is effective against roundworms(gastrointestinal, respiratory, renal, in the skin, etc.) and, depending on the delivery form and the dosage also against a number of external parasites such as lice, mites and various myiasis. However, it is ineffective against tapeworms and flukes, and at the usual use recommendations it doesn't control fleas, stable flies, mosquitoes, horse flies, multi-host ticks (e.g. Amblyomma spp, Dermacentor spp, Haemaphysalis spp, Ixodes spp, Rhipicephalus spp, etc.) and several other external parasites. In the last years it has been increasingly used in some countries against cattle ticks (Boophilus = Rhipicephalus microplus) and horn & buffalo flies (Haematobia irritans). Against cattle ticks, both as an injectable (at 0.2 mg/kg) and as a pour-on (0.5 mg/kg) control is usually better than with ivermectin (~95%) but without knock-down effect, i.e. the treated animals need 7-10 days to become more or less tick free. Control of horn & buffalo flies is initially sufficient (~85%) but falls down quickly after the first two weeks.
Doramectin(casno.117704-25-3) is moderately used in livestock, mainly in pour-ons and injectables. It is not used at all in pets or horses.
In most finished products, efficacy and safety depend not only on the amount of active ingredient(s) but also on their formulations (i.e. the type and amount of so-called inert ingredients), particularly in injectables and in topical pour-ons and spot-ons. These inert ingredients can significantly affect the pharmacokinetic behavior (e.g. absorption through the skin or from the injection site, distribution within the body, spreading throughout the body surface, etc). Generic products usually contain the same amount of active ingredient(s) as the original product, but often in quite different formulations. In many cases, the curative (therapeutic) efficacy of the different formulations is quite comparable, but the protective (prophylactic) efficacy that determines the length of protection against re-infestations may be rather different.
Comparison of pharmacokinetic profiles of Doramectin(casno.117704-25-3) and ivermectin pour-on formulations in cattle:
The plasma pharmacokinetics of Doramectin(casno.117704-25-3) and invermectin after topical administration (500 μg kg-1) were compared over a 50-day period in 24 young beef cattle. Observed maximum concentration (Cmax) and time to maximum concentration (Tmax) were determined directly from plasma concentrations for each animal. The area under the plasma concentration–time curve (AUC) and mean residence time (MRT) were calculated as indices of drug exposure and persistence. The Cmax of Doramectin(casno.117704-25-3) (12.2 ± 4.8 ng mL-1) and ivermectin (12.2 ± 6.0 ng mL-1) and Tmax of Doramectin(casno.117704-25-3) (4.3 ± 1.6 days) and ivermectin (3.4 ± 0.8 days) were not significantly different (p > 0.05). In contrast, the AUC of Doramectin(casno.117704-25-3) (168.0 ± 41.7 ng day ml-1) was significantly greater than that of ivermectin (115.5 ± 43.0 ng day ml-1). Furthermore, the range of AUC values calculated for ivermectin was wider than that obtained for Doramectin(casno.117704-25-3), extending from 51.3 to 182.3 ng day ml-1 for ivermectin versus 104.3–228.7 ng day mL-1 for Doramectin(casno.117704-25-3). The MRT was significantly greater for Doramectin(casno.117704-25-3) (12.8 ± 1.9 days) than for ivermectin (8.4 ± 1.5 days). It was concluded that a 500 μg kg-1 pour-on administration of Doramectin(casno.117704-25-3) and ivermectin led to an overall exposure as reflected by the mean AUC, that was 45% higher for Doramectin(casno.117704-25-3) compared to ivermectin and that the relative inter-individual variability was less for Doramectin(casno.117704-25-3) than for ivermectin.
Common Precautions of Doramectin(casno.117704-25-3):
Doramectin(casno.117704-25-3) should not be used for treating demodicosis or spirocerosis in dog breeds susceptible to the MDR1-allele mutation. Testing has shown a higher risk for toxicity in these breeds.
Adverse effects caused by Doramectin(casno.117704-25-3) are rare. Intramuscular injections have a greater chance of causing injection site blemishes than other types of administration. Possible negative side effects that have appeared when treating dogs for demodicosis include pupil dilation, blindness, lethargy, and coma.
Doramectin(casno.117704-25-3) should not be used in animals with a known allergy or hypersensitivity to the drug. A veterinarian should be contacted immediately if an overdose is suspected or any alarming symptoms occur.
Storage of Doramectin(casno.117704-25-3):
Doramectin(casno.117704-25-3) should be kept in a light resistant, childproof container at room temperature. The drug should not be exposed to light and it should be stored out of reach from children and pets.
keywords
Doramectin Quality
Doramectin Manufacturers
Doramectin Suppliers
Doramectin FDA
Doramectin USP.EP
Doramectin GMP
Doramectin price
Doramectin samples
Administration of Doramectin(casno.117704-25-3):
A typical dose of Doramectin(casno.117704-25-3) used for treating generalized demodicosis in dogs is .6 mg/kg once a week. For treating feline demodicosis, a typical dose is .6 mg/kg once a week. For cattle, a typical dose is .2-.5 mg/kg. For swine, a normal dose is .3 mg/kg. Should a scheduled dose be forgotten, it should be administered as soon as possible. If the next scheduled dose is near, the missed dose should be skipped and the regular medication schedule should resume.
Two doses should not be administered at the same time.
Doses may vary in different species, when the drug is given by a different route or concurrently with other medications, and with regards to a patient's age, breed, and health status. A veterinarian's dosing instructions and/or those printed on the medication label should be followed closely.